Gemcitabine CAS 95058-81-4 Healthy Antineoplastic Raw Material Drug
[USAN:BAN:INN];DDFC;LY 188011;LY188011 hydrochloride;Cytosine,
|Melting Point:||168.64 °C|
|Boiling Point:||482.7 °C at 760 mmHg|
|Flash Point:||245.7 °C|
Gemcitabine (2’,2’-difluorodeoxycytidine; dFdCyd) is a novel
deoxycytidine analogue with both structural and metabolic
similarities to cytarabine. It has a broad spectrum of antitumor
activity in preclinical murine leukemia and solid tumor models.
This drug requires intracellular phosphorylation that results in
the accumulation of difluorodeoxycytidine triphosphate (dFdCTP).
The dFdCTP competes with deoxycytidine triphosphate (dCTP) for
incorporation into DNA, which in turn inhibits DNA synthesis and
terminates DNA chain elongation. In addition, this drug reduces
intracellular deoxynucleoside triphosphate pools, presumably
through the inhibition of ribonucleotide reductase.
Gemcitabine(Gemzar) belongs to the group of medicines called
It is used alone or in combination with other medicines to treat
cancer of the breast, ovary, pancreas, and lung.
|Usage 3||Gemcitabine interferes with the growth of cancer cells.|
Gemcitabine is used alone or with other treatments/medications to
treat certain types of cancer (including breast cancer, non-small
cell lung cancer, ovarian cancer, pancreatic cancer, bladder
cancer, bone cancer, Ewing’s sarcoma, mesenchymal chondrosarcoma
osteosarcoma, dedifferentiated chondrosarcoma, head and neck
cancers-cancer of the nasopharynx, hepatobiliary cancers including
gallbladder cancer, Hodgkin lymphoma, kidney cancer, malignant
pleural mesothelioma, non Hodgkin lymphoma, non-melanoma skin
cancer – dermatofibrosarcoma protuberans (DFSP), occult primary,
small cell lung cancer, soft tissue sarcoma, testicular cancer,
thymic malignancies, uterine malignancies).
It is a chemotherapy drug that works by slowing or stopping the
growth of cancer cells. One commercial product of gemcitabine is
Gemzar, which is supplied in a sterile form for intravenous use